Literature DB >> 9723816

Best practice in therapeutic drug monitoring.

A S Gross1.   

Abstract

It is the goal of Therapeutic Drug Monitoring (TDM) to use drug concentrations to manage a patient's medication regimen and optimise outcome. Limited resources require that drug assays should only be performed when they do contribute to patient management. For this to be the case a therapeutic drug monitoring service has a far greater role than just therapeutic drug measuring. This article describes the roles and functions of a Best Practice TDM service. The features which can and should be strived for in each step of the TDM process-the decision to request a drug level, the biological sample, the request, laboratory measurement, communication of results by the laboratory, clinical interpretation and therapeutic management-are discussed.

Entities:  

Mesh:

Year:  1998        PMID: 9723816      PMCID: PMC1873661          DOI: 10.1046/j.1365-2125.1998.00770.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring and patient outcome. A review of the issues.

Authors:  A L Tonkin; F Bochner
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Community-based therapeutic drug monitoring. Useful development or unnecessary distraction?

Authors:  M Campbell
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 4.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

5.  Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.

Authors:  E el Desoky; J Meinshausen; K Bühl; G Engel; A Harings-Kaim; B Drewelow; U Klotz
Journal:  Ther Drug Monit       Date:  1993-08       Impact factor: 3.681

6.  Concentration- or effect-controlled clinical trials with sparse data.

Authors:  G Levy; W F Ebling; A Forrest
Journal:  Clin Pharmacol Ther       Date:  1994-07       Impact factor: 6.875

7.  Cyclosporin A monitoring in Australia: consensus recommendations.

Authors:  R G Morris; S E Tett; J E Ray
Journal:  Ther Drug Monit       Date:  1994-12       Impact factor: 3.681

8.  Effect of education on the appropriateness of serum drug concentration determination.

Authors:  D J Carroll; G E Austin; G V Stajich; R K Miyahara; J E Murphy; E S Ward
Journal:  Ther Drug Monit       Date:  1992-02       Impact factor: 3.681

Review 9.  Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness.

Authors:  R Eilers
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

Review 10.  The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

View more
  24 in total

Review 1.  Therapeutic drug monitoring in a developing country: an overview.

Authors:  N J Gogtay; N A Kshirsagar; S S Dalvi
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 3.  Review: therapeutic drug monitoring in pediatrics.

Authors:  Offie Porat Soldin; Steven J Soldin
Journal:  Ther Drug Monit       Date:  2002-02       Impact factor: 3.681

4.  Barriers and facilitators of appropriate vancomycin use: prescribing context is key.

Authors:  Joanne Oi Sze Chan; Melissa Therese Baysari; Jane Ellen Carland; Indy Sandaradura; Maria Moran; Richard Osborne Day
Journal:  Eur J Clin Pharmacol       Date:  2018-07-28       Impact factor: 2.953

5.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 6.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy.

Authors:  C T Rane; S S Dalvi; N J Gogtay; P U Shah; N A Kshirsagar
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

8.  Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation.

Authors:  Martin Šíma; Martin Vodička; Věra Marešová; Tomáš Šálek; Radomír Čabala; Ondřej Slanař
Journal:  Int J Clin Pharm       Date:  2017-08-08

9.  Prediction of cyclosporine A blood levels: an application of the adaptive-network-based fuzzy inference system (ANFIS) in assisting drug therapy.

Authors:  Sezer Gören; Adem Karahoca; Filiz Y Onat; M Zafer Gören
Journal:  Eur J Clin Pharmacol       Date:  2008-05-06       Impact factor: 2.953

Review 10.  Therapeutic drug monitoring in a developing nation: a clinical guide.

Authors:  Ndubuisi Nwobodo
Journal:  JRSM Open       Date:  2014-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.